The Gliosarcoma drugs in development market research report provides comprehensive information on the therapeutics under development for Gliosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Gliosarcoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Gliosarcoma and features dormant and discontinued products.
GlobalData tracks 41 drugs in development for Gliosarcoma by 34 companies/universities/institutes. The top development phase for Gliosarcoma is phase i with 18 drugs in that stage. The Gliosarcoma pipeline has 35 drugs in development by companies and six by universities/ institutes. Some of the companies in the Gliosarcoma pipeline products market are: Bristol-Myers Squibb, Merck and ImmunityBio.
The key targets in the Gliosarcoma pipeline products market include Programmed Cell Death 1 Ligand 1, Platelet Derived Growth Factor Receptor Alpha, and Platelet Derived Growth Factor Receptor Beta.
The key mechanisms of action in the Gliosarcoma pipeline product include Serine/Threonine Protein Kinase B Raf Inhibitor with two drugs in Phase III. The Gliosarcoma pipeline products include 15 routes of administration with the top ROA being Intravenous and ten key molecule types in the Gliosarcoma pipeline products market including Small Molecule, and Monoclonal Antibody.
Gliosarcoma overview
Gliosarcoma is a type of brain tumor that originates from glial cells. The tumor grows rapidly and symptom will vary depending on the exact location and size of the tumor. Common symptoms are headache, vomiting, cognitive problems, and drowsiness. Treatment of brain tumors depends upon the type and staging of the tumor, its size and position in the brain, as well as the age and other health problems of patient.
For a complete picture of Gliosarcoma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
